Table 2 Mean cost (US $) of each management modality, per 3-month period, according to the histologic type and stage
From: Economics of the clinical management of lung cancer in France: an analysis using a Markov model
Cost (US $) | Chemotherapy (%) | Radiotherapy (%) | Surgery (%) | Complications (%) | Monitoring (%) | TC (%) | Transport (%) | |
|---|---|---|---|---|---|---|---|---|
Loc Op NSCLC (n=58) | ||||||||
SOP | 5352 | 0 | 0 | 93.5 | 0.1 | 4.8 | 0 | 1.6 |
L1 | 14 812 | 22.4 | 19.6 | 44 | 7.5 | 0.5 | 0 | 6 |
L2 | 8976 | 33.6 | 23.6 | 17.4 | 13.7 | 0.8 | 0 | 10.9 |
R | 542 | 0 | 0 | 0 | 0 | 86.9 | 0 | 13.1 |
PC | 5801 | 0 | 0 | 0 | 0 | 0 | 88.9 | 11.1 |
Loc-Nop NSCLC (n=22) | ||||||||
L1 | 8725 | 28.8 | 41.6 | 0 | 14.4 | 0.6 | 0 | 14.6 |
L2 | 6810 | 26.9 | 44 | 0 | 18.8 | 1 | 0 | 9.3 |
R | 381 | 0 | 0 | 0 | 0 | 80.8 | 0 | 19.2 |
PC | 8315 | 0 | 0 | 0 | 0 | 0 | 89.2 | 10.8 |
LA-Ad NSCLC (n=21) | ||||||||
L1 | 15 918 | 27.4 | 10.9 | 51 | 3.1 | 0.1 | 0 | 7.5 |
L2 | 6162 | 55.8 | 21.6 | 5.5 | 2.9 | 0.8 | 0 | 13.4 |
R | 484 | 0 | 0 | 0 | 0 | 88.8 | 0 | 11.2 |
PC | 2982 | 0 | 0 | 0 | 0 | 0 | 96.3 | 3.7 |
LA-Nad NSCLC (n=99) | ||||||||
L1 | 10 424 | 46.9 | 29.3 | 0.6 | 10.5 | 0.2 | 1.5 | 11 |
L2 | 6790 | 40.6 | 27.6 | 5 | 5.8 | 0.6 | 9.3 | 11.1 |
R | 554 | 0 | 0 | 0 | 0 | 90.9 | 0 | 9.1 |
PC | 7140 | 0 | 0 | 0 | 0 | 0.5 | 95.2 | 4.3 |
Distant NSCLC (n=140) | ||||||||
L1 | 10 476 | 57 | 10 | 6.6 | 13.7 | 0.9 | 5.8 | 6 |
L2 | 6555 | 65.9 | 10.1 | 1.8 | 14.7 | 1.9 | 0 | 5.6 |
R | 539 | 0 | 0 | 0 | 0 | 84.5 | 0 | 15.5 |
PC | 5764 | 0 | 0 | 0 | 0 | 0.3 | 92.8 | 6.9 |
Local SCLC (n=36) | ||||||||
L1 | 12 436 | 42 | 27.9 | 1.6 | 14.9 | 2 | 0 | 11.6 |
L2 | 7311 | 62.5 | 13.6 | 0 | 11.1 | 5 | 0 | 7.7 |
R | 684 | 0 | 0 | 0 | 25.4 | 59.5 | 0 | 15.1 |
PC | 5279 | 0 | 0 | 0 | 0 | 0.6 | 85.7 | 13.7 |
Distant SCLC (n=52) | ||||||||
L1 | 10 718 | 52.1 | 8.8 | 3 | 26 | 4.1 | 0 | 6 |
L2 | 6100 | 72.2 | 7.6 | 0 | 5 | 7.4 | 1.3 | 6.5 |
R | 596 | 0 | 0 | 0 | 0 | 89.4 | 0 | 10.6 |
PC | 3521 | 0 | 0 | 0 | 0 | 0 | 90.4 | 9.6 |
